Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Allon Therapeutics Inc NPCUF

Allon Therapeutics, Inc. is a Canada-based Company, which develops treatments for neurodegenerative diseases. The Company is engaged in pre-clinical and clinical development of proprietary neuroprotective compounds which may be applied for the potential treatment of Alzheimer's Disease, Parkinson's Disease, senile dementia, glaucoma, traumatic head injury, neuronal damage due to stroke and other conditions involving neurodegeneration. The Company's drug, davunetide, is proceeding in a pivotal Phase 2/3 clinical trial in an orphan indication, progressive supranuclear palsy (PSP), under a Special Protocol Assessment (SPA) with the Food and Drug Administration (FDA).


GREY:NPCUF - Post by User

Post by modulexon Nov 28, 2017 9:09pm
209 Views
Post# 27050845

RAYMOND JAMES : OUTLOOK FOR A TAKEOVER

RAYMOND JAMES : OUTLOOK FOR A TAKEOVEROn January 25, 2017, RAYMOND JAMES Financial firm said : Our gut tells us the wait will have been well worth it. We see in NAPEC a promising growth company that continues to fly under the radar of most small cap investors. Our analysis suggests the stock presently carries little downside risk and solid upside as the specialty contractor capitalizes on the growing and dynamic market for electric and gas utility work, and its earnings reach an inflection point later this year. We assign NAPEC an Outperform rating and a target of $1.40, reflecting a potential return of 51% from current levels. ****the stock reached $1.40 today and could well rise to $1.75 by year-end 2017. In the end, it will become swallowed by an american company.
<< Previous
Bullboard Posts
Next >>